Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|June 25, 2009
Recent developments in the use of oral anticoagulantsMichael R LassenArchives of Internal Medicine|June 11, 2003
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind studyBengt I Eriksson, Michael R Lassen, The Journal of Arthroplasty|October 1, 2004
Efficacy of fondaparinux for thromboprophylaxis in hip fracture patientsBengt I Eriksson, Michael R Lassen, Clifford W ColwellThe New England Journal of Medicine|September 6, 2002
Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilizationMichael R Lassen, Lars C Borris, Roumen L NakovThrombosis|November 16, 2011
Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee ReplacementLars C Borris, Morten Breindahl, Michael R Lassen, et al.Journal of the Southern Orthopaedic Association|February 25, 2003
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialistKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.Archives of Internal Medicine|August 28, 2002
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.Current Opinion in Pulmonary Medicine|August 13, 2002
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismKenneth A Bauer, Bengt I Eriksson, Michael R Lassen, et al.Lancet (London, England)|June 7, 2002
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialAlexander G G Turpie, Kenneth A Bauer, Bengt I Eriksson, et al.Current Opinion in Hematology|August 13, 2003
Fondaparinux, the first selective factor Xa inhibitorAlexander G G Turpie, Bengt I Eriksson, Michael R Lassen, et al.Pageof 4